Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein
A small RNA ligand with high affinity for the HIV-1 Rev protein, generated by the SELEX in vitro evolution method, was used in a series of chemical modification studies to aid in determining the secondary structure of the ligand, to detect which modifications interfere with the binding of the ligand...
Gespeichert in:
Veröffentlicht in: | Journal of molecular biology 1994-01, Vol.235 (1), p.237-247 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 247 |
---|---|
container_issue | 1 |
container_start_page | 237 |
container_title | Journal of molecular biology |
container_volume | 235 |
creator | Jensen, Kirk B. Green, Louis MacDougal-Waugh, Sheela Tuerk, Craig |
description | A small RNA ligand with high affinity for the HIV-1 Rev protein, generated by the SELEX
in vitro evolution method, was used in a series of chemical modification studies to aid in determining the secondary structure of the ligand, to detect which modifications interfere with the binding of the ligand to Rev, and to find those modifiable groups that are protected from attack when bound to the Rev protein. This SELEX RNA ligand, like the high-affinity binding site of the Rev-responsive element, seems to bind the Rev protein within or along the major groove. There are two major regions of the RNA that interact with the Rev protein, and these regions appear to be close in space. Additionally, this high-affinity ligand has been used as the basis for an additional “biased randomization” SELEX procedure, in an effort to gain comprehensive information on the RNA sequences and structural elements necessary for efficient binding to the Rev protein. This complementary experimental approach supports the structural conclusions of our chemical modification data. |
doi_str_mv | 10.1016/S0022-2836(05)80030-0 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76333102</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022283605800300</els_id><sourcerecordid>16917308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-2207963dda908e1905b9d3429e514be3a292d84bf1d44415b7ad3f55497907713</originalsourceid><addsrcrecordid>eNqFkE1LJDEQhoMoOrr-BCEHEffQWvnqJCcZBleFYRfc1WtId6o10tOtSc-A_vptnWGunurwPm9V8RBywuCCASsv_wJwXnAjynNQPw2AgAJ2yISBsYUphdklky1yQA5zfgEAJaTZJ_uGG8ulmpD57NknXw-Y4ocfYt_RvqG-o7GjqzikvsjY4hgHev97Stv45LtAh54Oz0hv7x4LRhOu6GvqB4zdD7LX-Dbj8WYekYdf1_9mt8X8z83dbDovaslhKDgHbUsRgrdgkFlQlQ1CcouKyQqF55YHI6uGBSklU5X2QTRKSastaM3EETlb7x3vvi0xD24Rc41t6zvsl9npUgjBgH8LstIyLcCMoFqDdepzTti41xQXPr07Bu5Tt_vS7T5dOlDuS7eDsXeyObCsFhi2rY3fMT_d5D7Xvm2S7-qYt5gwxmrQI3a1xnC0toqYXK4jdjWGmEb7LvTxm0f-AwlrmKc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16917308</pqid></control><display><type>article</type><title>Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jensen, Kirk B. ; Green, Louis ; MacDougal-Waugh, Sheela ; Tuerk, Craig</creator><creatorcontrib>Jensen, Kirk B. ; Green, Louis ; MacDougal-Waugh, Sheela ; Tuerk, Craig</creatorcontrib><description>A small RNA ligand with high affinity for the HIV-1 Rev protein, generated by the SELEX
in vitro evolution method, was used in a series of chemical modification studies to aid in determining the secondary structure of the ligand, to detect which modifications interfere with the binding of the ligand to Rev, and to find those modifiable groups that are protected from attack when bound to the Rev protein. This SELEX RNA ligand, like the high-affinity binding site of the Rev-responsive element, seems to bind the Rev protein within or along the major groove. There are two major regions of the RNA that interact with the Rev protein, and these regions appear to be close in space. Additionally, this high-affinity ligand has been used as the basis for an additional “biased randomization” SELEX procedure, in an effort to gain comprehensive information on the RNA sequences and structural elements necessary for efficient binding to the Rev protein. This complementary experimental approach supports the structural conclusions of our chemical modification data.</description><identifier>ISSN: 0022-2836</identifier><identifier>EISSN: 1089-8638</identifier><identifier>DOI: 10.1016/S0022-2836(05)80030-0</identifier><identifier>PMID: 8289245</identifier><identifier>CODEN: JMOBAK</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>AIDS/HIV ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Base Composition ; Base Sequence ; Biological and medical sciences ; Computer Graphics ; Consensus Sequence ; DNA-Directed RNA Polymerases - metabolism ; Gene Products, rev - metabolism ; HIV-1 - metabolism ; human immunodeficiency virus 1 ; Ligands ; Medical sciences ; Models, Molecular ; Molecular Sequence Data ; Nucleic Acid Conformation ; Oligodeoxyribonucleotides ; Pharmacology. Drug treatments ; protein-RNA interaction ; Rev ; rev Gene Products, Human Immunodeficiency Virus ; RNA ligand ; RNA, Viral - chemistry ; RNA, Viral - metabolism ; RRE ; SELEX ; Transcription, Genetic ; Viral Proteins</subject><ispartof>Journal of molecular biology, 1994-01, Vol.235 (1), p.237-247</ispartof><rights>1994 Academic Press Limited</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-2207963dda908e1905b9d3429e514be3a292d84bf1d44415b7ad3f55497907713</citedby><cites>FETCH-LOGICAL-c420t-2207963dda908e1905b9d3429e514be3a292d84bf1d44415b7ad3f55497907713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022283605800300$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3889707$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8289245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jensen, Kirk B.</creatorcontrib><creatorcontrib>Green, Louis</creatorcontrib><creatorcontrib>MacDougal-Waugh, Sheela</creatorcontrib><creatorcontrib>Tuerk, Craig</creatorcontrib><title>Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein</title><title>Journal of molecular biology</title><addtitle>J Mol Biol</addtitle><description>A small RNA ligand with high affinity for the HIV-1 Rev protein, generated by the SELEX
in vitro evolution method, was used in a series of chemical modification studies to aid in determining the secondary structure of the ligand, to detect which modifications interfere with the binding of the ligand to Rev, and to find those modifiable groups that are protected from attack when bound to the Rev protein. This SELEX RNA ligand, like the high-affinity binding site of the Rev-responsive element, seems to bind the Rev protein within or along the major groove. There are two major regions of the RNA that interact with the Rev protein, and these regions appear to be close in space. Additionally, this high-affinity ligand has been used as the basis for an additional “biased randomization” SELEX procedure, in an effort to gain comprehensive information on the RNA sequences and structural elements necessary for efficient binding to the Rev protein. This complementary experimental approach supports the structural conclusions of our chemical modification data.</description><subject>AIDS/HIV</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Base Composition</subject><subject>Base Sequence</subject><subject>Biological and medical sciences</subject><subject>Computer Graphics</subject><subject>Consensus Sequence</subject><subject>DNA-Directed RNA Polymerases - metabolism</subject><subject>Gene Products, rev - metabolism</subject><subject>HIV-1 - metabolism</subject><subject>human immunodeficiency virus 1</subject><subject>Ligands</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Molecular Sequence Data</subject><subject>Nucleic Acid Conformation</subject><subject>Oligodeoxyribonucleotides</subject><subject>Pharmacology. Drug treatments</subject><subject>protein-RNA interaction</subject><subject>Rev</subject><subject>rev Gene Products, Human Immunodeficiency Virus</subject><subject>RNA ligand</subject><subject>RNA, Viral - chemistry</subject><subject>RNA, Viral - metabolism</subject><subject>RRE</subject><subject>SELEX</subject><subject>Transcription, Genetic</subject><subject>Viral Proteins</subject><issn>0022-2836</issn><issn>1089-8638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LJDEQhoMoOrr-BCEHEffQWvnqJCcZBleFYRfc1WtId6o10tOtSc-A_vptnWGunurwPm9V8RBywuCCASsv_wJwXnAjynNQPw2AgAJ2yISBsYUphdklky1yQA5zfgEAJaTZJ_uGG8ulmpD57NknXw-Y4ocfYt_RvqG-o7GjqzikvsjY4hgHev97Stv45LtAh54Oz0hv7x4LRhOu6GvqB4zdD7LX-Dbj8WYekYdf1_9mt8X8z83dbDovaslhKDgHbUsRgrdgkFlQlQ1CcouKyQqF55YHI6uGBSklU5X2QTRKSastaM3EETlb7x3vvi0xD24Rc41t6zvsl9npUgjBgH8LstIyLcCMoFqDdepzTti41xQXPr07Bu5Tt_vS7T5dOlDuS7eDsXeyObCsFhi2rY3fMT_d5D7Xvm2S7-qYt5gwxmrQI3a1xnC0toqYXK4jdjWGmEb7LvTxm0f-AwlrmKc</recordid><startdate>19940107</startdate><enddate>19940107</enddate><creator>Jensen, Kirk B.</creator><creator>Green, Louis</creator><creator>MacDougal-Waugh, Sheela</creator><creator>Tuerk, Craig</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19940107</creationdate><title>Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein</title><author>Jensen, Kirk B. ; Green, Louis ; MacDougal-Waugh, Sheela ; Tuerk, Craig</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-2207963dda908e1905b9d3429e514be3a292d84bf1d44415b7ad3f55497907713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>AIDS/HIV</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Base Composition</topic><topic>Base Sequence</topic><topic>Biological and medical sciences</topic><topic>Computer Graphics</topic><topic>Consensus Sequence</topic><topic>DNA-Directed RNA Polymerases - metabolism</topic><topic>Gene Products, rev - metabolism</topic><topic>HIV-1 - metabolism</topic><topic>human immunodeficiency virus 1</topic><topic>Ligands</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Molecular Sequence Data</topic><topic>Nucleic Acid Conformation</topic><topic>Oligodeoxyribonucleotides</topic><topic>Pharmacology. Drug treatments</topic><topic>protein-RNA interaction</topic><topic>Rev</topic><topic>rev Gene Products, Human Immunodeficiency Virus</topic><topic>RNA ligand</topic><topic>RNA, Viral - chemistry</topic><topic>RNA, Viral - metabolism</topic><topic>RRE</topic><topic>SELEX</topic><topic>Transcription, Genetic</topic><topic>Viral Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jensen, Kirk B.</creatorcontrib><creatorcontrib>Green, Louis</creatorcontrib><creatorcontrib>MacDougal-Waugh, Sheela</creatorcontrib><creatorcontrib>Tuerk, Craig</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jensen, Kirk B.</au><au>Green, Louis</au><au>MacDougal-Waugh, Sheela</au><au>Tuerk, Craig</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein</atitle><jtitle>Journal of molecular biology</jtitle><addtitle>J Mol Biol</addtitle><date>1994-01-07</date><risdate>1994</risdate><volume>235</volume><issue>1</issue><spage>237</spage><epage>247</epage><pages>237-247</pages><issn>0022-2836</issn><eissn>1089-8638</eissn><coden>JMOBAK</coden><abstract>A small RNA ligand with high affinity for the HIV-1 Rev protein, generated by the SELEX
in vitro evolution method, was used in a series of chemical modification studies to aid in determining the secondary structure of the ligand, to detect which modifications interfere with the binding of the ligand to Rev, and to find those modifiable groups that are protected from attack when bound to the Rev protein. This SELEX RNA ligand, like the high-affinity binding site of the Rev-responsive element, seems to bind the Rev protein within or along the major groove. There are two major regions of the RNA that interact with the Rev protein, and these regions appear to be close in space. Additionally, this high-affinity ligand has been used as the basis for an additional “biased randomization” SELEX procedure, in an effort to gain comprehensive information on the RNA sequences and structural elements necessary for efficient binding to the Rev protein. This complementary experimental approach supports the structural conclusions of our chemical modification data.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>8289245</pmid><doi>10.1016/S0022-2836(05)80030-0</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2836 |
ispartof | Journal of molecular biology, 1994-01, Vol.235 (1), p.237-247 |
issn | 0022-2836 1089-8638 |
language | eng |
recordid | cdi_proquest_miscellaneous_76333102 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | AIDS/HIV Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Base Composition Base Sequence Biological and medical sciences Computer Graphics Consensus Sequence DNA-Directed RNA Polymerases - metabolism Gene Products, rev - metabolism HIV-1 - metabolism human immunodeficiency virus 1 Ligands Medical sciences Models, Molecular Molecular Sequence Data Nucleic Acid Conformation Oligodeoxyribonucleotides Pharmacology. Drug treatments protein-RNA interaction Rev rev Gene Products, Human Immunodeficiency Virus RNA ligand RNA, Viral - chemistry RNA, Viral - metabolism RRE SELEX Transcription, Genetic Viral Proteins |
title | Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T07%3A16%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20an%20in%20vitro-selected%20RNA%20ligand%20to%20the%20HIV-1%20rev%20protein&rft.jtitle=Journal%20of%20molecular%20biology&rft.au=Jensen,%20Kirk%20B.&rft.date=1994-01-07&rft.volume=235&rft.issue=1&rft.spage=237&rft.epage=247&rft.pages=237-247&rft.issn=0022-2836&rft.eissn=1089-8638&rft.coden=JMOBAK&rft_id=info:doi/10.1016/S0022-2836(05)80030-0&rft_dat=%3Cproquest_cross%3E16917308%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16917308&rft_id=info:pmid/8289245&rft_els_id=S0022283605800300&rfr_iscdi=true |